- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05035121
Effect of Nutrition Supplementation Combined With Resistance Exercise in Elderly With Sarcopenia.
August 31, 2021 updated by: Jiun-Rong Chen, Taipei Medical University
Effects of Milk or Soy Milk Combined With Mild Resistance Exercise on the Muscle Mass and Muscle Strength in Very Old Nursing Home Residents With Sarcopenia
The purpose of this study was determine whether milk or soy milk supplements combined with resistance exercise improved sarcopenia in the elderly.
This study was randomized controlled trail that recruited elderly people ≧65 years old with sarcopenia in the nursing home of Taipei Veterans General Hospital Su-Ao and Yuanshan Branch from June 2017 to December, 2017.
The participants were divided into three groups, such as control, milk supplement and soy milk supplement.
The milk and soy milk groups provided 200 mL milk or soy milk two times per day.
Moreover, all participants joined the resistance exercise training program, three times per week (30 min/time).
After 12 weeks, the anthropometry, sarcopenia index, blood biochemical index, nutrition status index, inflammation index, insulin resistance index, and dietary intake were measured.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The anthropometry data included body weight and body fat.
The sarcopenia index included appendicular skeletal muscle mass index, calf circumferences, hand grip and gait speed.
Moreover, blood biochemical index (liver function as ALT, kidney function as creatinine), nutrition status index (prealbumin, 25-hydroxyvitamin D) were also analyzed.
The blood hsCRP level was as inflammation index and insulin resistance index included fasting blood sugar, insulin, HbA1c and HOMA-IR.
The daily dietary intake were also recorded.
Study Type
Interventional
Enrollment (Actual)
35
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
New Taipei City, Taiwan
- Taipei Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years to 99 years (OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≧ 65 years old
- No allergies to milk and soy milk
- Sarcopenia cases (AWGS)
- Active ability
Exclusion Criteria:
- End-of-life patient or estimated death within six months
- Last stage of cancer
- Chronic kidney disease stage 4
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: milk supplement
The milk group provided 200 mL milk two times per day.
The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
|
Intervention groups provided 200 mL long life milk two times per day at morning and afternoon.
The participants joined the resistance exercise training program, three times per week (30 min/time)
The participants joined the resistance exercise training program, three times per week (30 min/time)
|
|
EXPERIMENTAL: soy milk supplement
The soy milk group provided 200 mL soy milk two times per day.
The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
|
The participants joined the resistance exercise training program, three times per week (30 min/time)
Intervention groups provided 200 mL long life soy milk two times per day at morning and afternoon.
The participants joined the resistance exercise training program, three times per week (30 min/time)
|
|
PLACEBO_COMPARATOR: control
The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
|
The participants joined the resistance exercise training program, three times per week (30 min/time)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
appendicular skeletal muscle mass in kilograms
Time Frame: baseline
|
The appendicular skeletal muscle mass was evaluated by bioelectrical impedance (BIA) analysis (Inbody S10, Inbody Inc., Seoul, South Korea)
|
baseline
|
|
Change from baseline appendicular skeletal muscle mass at 6 weeks
Time Frame: 6 weeks
|
The appendicular skeletal muscle mass was evaluated by bioelectrical impedance (BIA) analysis (Inbody S10, Inbody Inc., Seoul, South Korea)
|
6 weeks
|
|
Change from baseline appendicular skeletal muscle mass at 12 weeks
Time Frame: 12 weeks
|
The appendicular skeletal muscle mass was evaluated by bioelectrical impedance (BIA) analysis (Inbody S10, Inbody Inc., Seoul, South Korea)
|
12 weeks
|
|
height in meters
Time Frame: baseline
|
Height was measured by height meter
|
baseline
|
|
Change baseline weeks height at 6 weeks
Time Frame: 6 weeks
|
Height was measured by height meter
|
6 weeks
|
|
Change from baseline height at 12 weeks
Time Frame: 12 weeks
|
Height was measured by height meter
|
12 weeks
|
|
appendicular skeletal muscle mass index in kg/m^2
Time Frame: baseline
|
The appendicular skeletal muscle mass muscle mass and height was combined to report appendicular skeletal muscle mass index in kg/m^2.
|
baseline
|
|
Change from baseline appendicular skeletal muscle mass index at 6 weeks
Time Frame: 6 weeks
|
The appendicular skeletal muscle mass muscle mass and height was combined to report appendicular skeletal muscle mass index in kg/m^2.
|
6 weeks
|
|
Change from baseline appendicular skeletal muscle mass index at 12 weeks
Time Frame: 12 weeks
|
The appendicular skeletal muscle mass muscle mass and height was combined to report appendicular skeletal muscle mass index in kg/m^2.
|
12 weeks
|
|
calf circumferences in centimeter
Time Frame: baseline
|
calf circumferences (cm) was measured by using a measuring tape to go around the thickest point of the calf and stick tightly without squeezing the skin.
|
baseline
|
|
Change from baseline calf circumferences at 6 weeks
Time Frame: 6 weeks
|
calf circumferences (cm) was measured by using a measuring tape to go around the thickest point of the calf and stick tightly without squeezing the skin.
|
6 weeks
|
|
Change from baseline calf circumferences at 12 weeks
Time Frame: 12 weeks
|
calf circumferences (cm) was measured by using a measuring tape to go around the thickest point of the calf and stick tightly without squeezing the skin.
|
12 weeks
|
|
hand grip in kilograms
Time Frame: baseline
|
The muscle strength was evaluated with the hand-grip strength (kg) using a Smedley dynamometer (TTM-YD, Tsutsumi Industries, Tokyo, Japan)
|
baseline
|
|
Change from baseline hand grip at 6 weeks
Time Frame: 6 weeks
|
The muscle strength was evaluated with the hand-grip strength (kg) using a Smedley dynamometer (TTM-YD, Tsutsumi Industries, Tokyo, Japan)
|
6 weeks
|
|
Change from baseline hand grip at 12 weeks
Time Frame: 12 weeks
|
The muscle strength was evaluated with the hand-grip strength (kg) using a Smedley dynamometer (TTM-YD, Tsutsumi Industries, Tokyo, Japan)
|
12 weeks
|
|
gait speed in meter per second
Time Frame: baseline
|
The gait speed test was performed by recording the average time of walking 6 meters and representing with the distance (m) per second.
|
baseline
|
|
Change from baseline gait speed at 6 weeks
Time Frame: 6 weeks
|
The gait speed test was performed by recording the average time of walking 6 meters and representing with the distance (m) per second.
|
6 weeks
|
|
Change from baseline gait speed at 12 weeks
Time Frame: 12 weeks
|
The gait speed test was performed by recording the average time of walking 6 meters and representing with the distance (m) per second.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
blood alanine transaminase activity in U/L
Time Frame: baseline
|
The blood alanine transaminase (ALT) activity in U/L was measured as liver function index by automated clinical chemistry analyzer.
|
baseline
|
|
Change from baseline blood alanine transaminase activity at 12 weeks
Time Frame: 12 weeks
|
The blood alanine transaminase (ALT) activity in U/L was measured as liver function index by automated clinical chemistry analyzer.
|
12 weeks
|
|
blood creatinine level in mg/dL
Time Frame: baseline
|
The blood creatinine level was measured as kidney function by automated clinical chemistry analyzer.
|
baseline
|
|
Change from baseline blood creatinine level at 12 weeks
Time Frame: 12 weeks
|
The blood creatinine level was measured as kidney function by automated clinical chemistry analyzer.
|
12 weeks
|
|
blood prealbumin level in mg/dL
Time Frame: baseline
|
The blood prealbumin level in mg/dL as the index of nutritional status were measured by automated clinical chemistry analyzer.
|
baseline
|
|
Change from baseline blood prealbumin level at 12 weeks
Time Frame: 12 weeks
|
The blood prealbumin level in mg/dL as the index of nutritional status were measured by automated clinical chemistry analyzer.
|
12 weeks
|
|
blood 25-hydroxyvitamin D level in ng/mL
Time Frame: baseline
|
The blood 25-hydroxyvitamin D level in ng/mL as the index of nutritional status were measured by automated clinical chemistry analyzer.
|
baseline
|
|
Change from baseline blood 25-hydroxyvitamin D level at 12 weeks
Time Frame: 12 weeks
|
The blood 25-hydroxyvitamin D level in ng/mL as the index of nutritional status were measured by automated clinical chemistry analyzer.
|
12 weeks
|
|
High sensitive C-reactive protein in mg/dL
Time Frame: baseline
|
High sensitive C-reactive protein (hsCRP) as the inflammatory indicator were measured by automated clinical chemistry analyzer.
|
baseline
|
|
Change from baseline High sensitive C-reactive protein at 12 weeks
Time Frame: 12 weeks
|
High sensitive C-reactive protein (hsCRP) as the inflammatory indicator were measured by automated clinical chemistry analyzer.
|
12 weeks
|
|
blood fasting blood sugar in mg/dL
Time Frame: baseline
|
The blood fasting blood sugar level in mg/dL as the insulin resistance index was measured by automated clinical chemistry analyzer.
|
baseline
|
|
Change from baseline blood fasting blood sugar at 12 weeks
Time Frame: 12 weeks
|
The blood fasting blood sugar level in mg/dL as the insulin resistance index was measured by automated clinical chemistry analyzer.
|
12 weeks
|
|
blood insulin level in milli-international unit/L
Time Frame: baseline
|
The blood insulin level in milli-international unit/L as the insulin resistance index was measured by commercial kits.
|
baseline
|
|
Change from baseline blood insulin level at 12 weeks
Time Frame: 12 weeks
|
The blood insulin level in milli-international unit/L as the insulin resistance index was measured by commercial kits.
|
12 weeks
|
|
blood HbA1c in percentage
Time Frame: baseline
|
The blood HbA1c in percentage as the insulin resistance index was measured by automated clinical chemistry analyzer.
|
baseline
|
|
Change from baseline blood HbA1c at 12 weeks
Time Frame: 12 weeks
|
The blood HbA1c in percentage as the insulin resistance index was measured by automated clinical chemistry analyzer.
|
12 weeks
|
|
Homeostasis model assessment-insulin resistance index (HOMA-IR)
Time Frame: baseline
|
HOMA-IR was calculated according to the formula: fasting insulin (μU/mL) x fasting glucose (mmol/L)/22.5
|
baseline
|
|
Change from baseline homeostasis model assessment-insulin resistance index (HOMA-IR) at 12 weeks
Time Frame: 12 weeks
|
HOMA-IR was calculated according to the formula: fasting insulin (μU/mL) x fasting glucose (mmol/L)/22.5
|
12 weeks
|
|
blood insulin-like growth factor 1 in mg/dL
Time Frame: baseline
|
The blood insulin-like growth factor 1 (IGF-1) level considered to be related with the protein synthesis in muscle was measured by chemiluminescence immunoassay.
|
baseline
|
|
Change from baseline blood insulin-like growth factor 1 at 12 weeks
Time Frame: 12 weeks
|
The blood insulin-like growth factor 1 (IGF-1) level considered to be related with the protein synthesis in muscle was measured by chemiluminescence immunoassay.
|
12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
diet assessment
Time Frame: baseline
|
Dietary data were collected based on the meal menu of the nursing home including one weekday and two weekends at the beginning and the end of the experiment.
Caregivers recorded the actual food intake by participants.
The intake of total energy, carbohydrate, protein and fat was analyzed with E Kitchen Nutrients Analysis Software (E Kitchen Business, Taichung, Taiwan) based on the food and nutrient database created by the Organization Act of the Food and Drug Administration, Ministry of Health and Welfare, Taiwan.
|
baseline
|
|
Change from baseline diet assessment at 12 weeks
Time Frame: 12 weeks
|
Dietary data were collected based on the meal menu of the nursing home including one weekday and two weekends at the beginning and the end of the experiment.
Caregivers recorded the actual food intake by participants.
The intake of total energy, carbohydrate, protein and fat was analyzed with E Kitchen Nutrients Analysis Software (E Kitchen Business, Taichung, Taiwan) based on the food and nutrient database created by the Organization Act of the Food and Drug Administration, Ministry of Health and Welfare, Taiwan.
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
March 24, 2017
Primary Completion (ACTUAL)
January 23, 2018
Study Completion (ACTUAL)
March 23, 2018
Study Registration Dates
First Submitted
May 24, 2021
First Submitted That Met QC Criteria
August 31, 2021
First Posted (ACTUAL)
September 5, 2021
Study Record Updates
Last Update Posted (ACTUAL)
September 5, 2021
Last Update Submitted That Met QC Criteria
August 31, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- N201702034
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcopenia
-
Cairo UniversityNot yet recruitingGeriatric SarcopeniaEgypt
-
University Hospital, BonnRecruiting
-
Shanghai Yueyang Integrated Medicine HospitalShanghai University of Traditional Chinese Medicine; DongE E Jiao Coporation... and other collaboratorsNot yet recruiting
-
Assiut UniversityNot yet recruiting
-
TNF Pharmaceuticals, Inc.Not yet recruitingFrailty | Sarcopenia in Elderly | Frailty/Sarcopenia | Frailty in Older Adults
-
University of ExtremaduraCompletedSarcopenia in Elderly | Institutionalized Older Adults | HIITSpain
-
Medway NHS Foundation TrustNot yet recruitingFalls | Sarcopenia in ElderlyUnited Kingdom
-
University of Texas at AustinNot yet recruitingExercise Training and SarcopeniaUnited States
-
Animuscure Inc.Recruiting
-
West China HospitalNot yet recruitingSarcopenia in Elderly
Clinical Trials on milk supplement
-
a2 Milk Company Ltd.Completed
-
National Center for Research Resources (NCRR)Baylor College of MedicineCompletedSepsis | Necrotizing EnterocolitisUnited States
-
NestléUniversity of the PhilippinesCompletedDiarrhea | Acute Respiratory InfectionPhilippines
-
The University of QueenslandMonash University; Murdoch Childrens Research Institute; University of Melbourne and other collaboratorsRecruitingBreastfeeding | Mental Health Issue | Neonatal Hypoglycemia | Hospital Length of Stay | Neonatal Intensive Care Unit | Metabolic Complication | Cows Milk AllergyAustralia
-
Helsinki University Central HospitalCompleted
-
NestléCompletedGrowth | Learning | ToddlersPhilippines
-
FrieslandCampinaUniversiti Sains MalaysiaCompletedAt Risk or Stunted ChildrenMalaysia
-
Société des Produits Nestlé (SPN)CompletedPicky Eating BehaviorsChina
-
Brigham and Women's HospitalCompletedVitamin d Deficiency
-
Loughborough UniversityRecruitingCardiovascular Diseases | Overweight or Obesity | Cognition | Postmenopausal Women | Cardiometabolic Risk FactorsUnited Kingdom